You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameProchlorperazine
Accession NumberDB00433  (APRD00624)
TypeSmall Molecule
GroupsApproved, Vet Approved
Description

A phenothiazine antipsychotic used principally in the treatment of nausea; vomiting; and vertigo. It is more likely than chlorpromazine to cause extrapyramidal disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p612)

Structure
Thumb
Synonyms
2-Chloro-10-(3-(1-methyl-4-piperazinyl)propyl)-phenothiazine
2-Chloro-10-(3-(4-methyl-1-piperazinyl)propyl)phenothiazine
3-Chloro-10-(3-(1-methyl-4-piperazinyl)propyl)phenothiazine
3-Chloro-10-(3-(4-methyl-1-piperazinyl)propyl)phenothiazine
Capazine
Chlormeprazine
Chloro-3 (N-methylpiperazinyl-3 propyl)-10 phenothiazine
Chloropernazine
Emetiral
N-(gamma-(4'-Methylpiperazinyl-1')propyl)-3-chlorophenothiazine
Prochlorperazin
Prochlorpérazine
Prochlorperazinum
Prochlorpermazine
Prochlorpromazine
Procloperazine
Proclorperazina
External Identifiers
  • Bayer A 173
  • RP 6140
  • SKF 4657
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Nu-prochlor Tab 10mgtablet10 mgoralNu Pharm Inc1992-12-312012-09-04Canada
Nu-prochlor Tab 5mgtablet5 mgoralNu Pharm Inc1992-12-312012-09-04Canada
PMS Prochlorperazine Inj 5mg/mlsolution5 mgintramuscular; intravenousPharmascience Inc1989-12-31Not applicableCanada
PMS-prochlorperazine Suppositoires 10mgsuppository10 mgrectalPharmascience Inc1989-12-31Not applicableCanada
PMS-prochlorperazine Tab 10mgtablet10 mgoralPharmascience Inc1989-12-31Not applicableCanada
PMS-prochlorperazine Tab 5mgtablet5 mgoralPharmascience Inc1989-12-31Not applicableCanada
Prochlorazinetablet10 mgoralAa Pharma Inc2000-02-09Not applicableCanada
Prochlorazinetablet5 mgoralAa Pharma Inc2000-02-09Not applicableCanada
Prochlorperazine Mesylate Inj 5mg/mlliquid5 mgintramuscular; intravenousSandoz Canada Incorporated1989-12-31Not applicableCanada
Sandoz Prochlorperazinesuppository10 mgrectalSandoz Canada Incorporated1989-12-31Not applicableCanada
Stemetilsolution5 mgintramuscular; intravenousSanofi Aventis Canada Inc1957-12-312007-01-30Canada
Stemetilsuppository10 mgrectalSanofi Aventis Canada Inc1958-12-312006-07-28Canada
Stemetil Liq 5mg/5mlsyrup5 mgoralAventis Pharma Inc1958-12-312005-08-01Canada
Stemetil Tab 10mgtablet10 mgoralAventis Pharma Inc1957-12-312005-08-01Canada
Stemetil Tab 5mgtablet5 mgoralAventis Pharma Inc1957-12-312005-08-01Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Compazinetablet, film coated5 mg/1oralPBM Pharmaceuticals, Inc.2014-04-012016-01-27Us
Compazinesuppository25 mg/1rectalPBM Pharmaceuticals, Inc2013-07-01Not applicableUs
Compazinetablet, film coated10 mg/1oralPBM Pharmaceuticals, Inc.2014-04-012016-01-31Us
Comprosuppository25 mg/1rectalPaddock Laboratories, LLC2000-09-01Not applicableUs
Comprosuppository25 mg/1rectalPd Rx Pharmaceuticals, Inc.2000-09-01Not applicableUs
Prochlorperazinetablet10 mg/1oralSTAT Rx USA LLC2009-07-29Not applicableUs
Prochlorperazinesuppository25 mg/1rectalPhysicians Total Care, Inc.2001-07-20Not applicableUs
Prochlorperazinesuppository25 mg/1rectalG&W Laboratories, Inc.1993-11-30Not applicableUs
Prochlorperazine Edisylateinjection5 mg/mLintramuscular; intravenousCardinal Health2004-07-26Not applicableUs
Prochlorperazine Edisylateinjection5 mg/mLintramuscular; intravenousHeritage Pharmaceuticals Inc.2015-06-26Not applicableUs
Prochlorperazine Edisylateinjection5 mg/mLintramuscular; intravenousHeritage Pharmaceuticals Inc.2015-01-14Not applicableUs
Prochlorperazine Edisylateinjection5 mg/mLintramuscular; intravenousHeritage Pharmaceuticals Inc.2012-03-26Not applicableUs
Prochlorperazine Edisylateinjection5 mg/mLintramuscular; intravenousWest Ward Pharmaceuticals Corp.1989-08-29Not applicableUs
Prochlorperazine Edisylateinjection5 mg/mLintramuscular; intravenousPhysicians Total Care, Inc.2004-07-26Not applicableUs
Prochlorperazine Edisylateinjection5 mg/mLintramuscular; intravenousBaxter Healthcare Corporation2011-01-14Not applicableUs
Prochlorperazine Edisylateinjection5 mg/mLintramuscular; intravenousCardinal Health2012-03-26Not applicableUs
Prochlorperazine Edisylateinjection10 mg/2mLintramuscular; intravenousGeneral Injectables & Vaccines, Inc2010-08-01Not applicableUs
Prochlorperazine Edisylateinjection5 mg/mLintramuscularREMEDYREPACK INC.2015-03-12Not applicableUs
Prochlorperazine Maleatetablet10 mg/1oralBlenheim Pharmacal, Inc.2013-11-18Not applicableUs
Prochlorperazine Maleatetablet10 mg/1oralREMEDYREPACK INC.2013-06-03Not applicableUs
Prochlorperazine Maleatetablet, film coated5 mg/1oralPd Rx Pharmaceuticals, Inc.2010-12-13Not applicableUs
Prochlorperazine Maleatetablet10 mg/1oralPreferred Pharmaceuticals, Inc.2014-05-13Not applicableUs
Prochlorperazine Maleatetablet10 mg/1oralREMEDYREPACK INC.2011-04-11Not applicableUs
Prochlorperazine Maleatetablet, film coated5 mg/1oralTeva Pharmaceuticals USA Inc1996-07-25Not applicableUs
Prochlorperazine Maleatetablet, film coated5 mg/1oralA S Medication Solutions Llc1996-07-25Not applicableUs
Prochlorperazine Maleatetablet, film coated5 mg/1oralA S Medication Solutions Llc1996-07-25Not applicableUs
Prochlorperazine Maleatetablet10 mg/1oralJUBILANT CADISTA PHARMACEUTICALS, INC.1998-03-01Not applicableUs
Prochlorperazine Maleatetablet, film coated10 mg/1oralAvera Mc Kennan Hospital2015-09-08Not applicableUs
Prochlorperazine Maleatetablet, film coated5 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2010-12-13Not applicableUs
Prochlorperazine Maleatetablet, film coated10 mg/1oralA S Medication Solutions Llc1996-07-25Not applicableUs
Prochlorperazine Maleatetablet5 mg/1oralAidarex Pharmaceuticals LLC1998-03-01Not applicableUs
Prochlorperazine Maleatetablet, film coated5 mg/1oralREMEDYREPACK INC.2013-06-03Not applicableUs
Prochlorperazine Maleatetablet, film coated10 mg/1oralPd Rx Pharmaceuticals, Inc.2010-12-13Not applicableUs
Prochlorperazine Maleatetablet5 mg/1oralPreferred Pharmaceuticals, Inc.2012-07-26Not applicableUs
Prochlorperazine Maleatetablet, film coated5 mg/1oralPd Rx Pharmaceuticals, Inc.1996-11-18Not applicableUs
Prochlorperazine Maleatetablet, film coated10 mg/1oralSandoz Inc1996-07-19Not applicableUs
Prochlorperazine Maleatetablet, film coated5 mg/1oralA S Medication Solutions Llc1996-07-19Not applicableUs
Prochlorperazine Maleatetablet, film coated5 mg/1oralPhysicians Total Care, Inc.2003-02-10Not applicableUs
Prochlorperazine Maleatetablet5 mg/1oralbryant ranch prepack1998-03-01Not applicableUs
Prochlorperazine Maleatetablet5 mg/1oralREMEDYREPACK INC.2012-09-12Not applicableUs
Prochlorperazine Maleatetablet, film coated10 mg/1oralPreferred Pharmaceuticals, Inc.2013-03-14Not applicableUs
Prochlorperazine Maleatetablet, film coated5 mg/1oralPd Rx Pharmaceuticals, Inc.2010-12-13Not applicableUs
Prochlorperazine Maleatetablet, film coated5 mg/1oralSandoz Inc1996-07-19Not applicableUs
Prochlorperazine Maleatetablet, film coated5 mg/1oralA S Medication Solutions Llc1996-07-19Not applicableUs
Prochlorperazine Maleatetablet, film coated10 mg/1oralbryant ranch prepack1996-07-25Not applicableUs
Prochlorperazine Maleatetablet5 mg/1oralLiberty Pharmaceuticals, Inc.1998-03-01Not applicableUs
Prochlorperazine Maleatetablet5 mg/61oralNorthwind Pharmaceuticals2014-04-28Not applicableUs
Prochlorperazine Maleatetablet, film coated5 mg/1oralCardinal Health2011-01-28Not applicableUs
Prochlorperazine Maleatetablet, film coated10 mg/1oralAmerican Health Packaging2014-09-292016-01-31Us
Prochlorperazine Maleatetablet, film coated5 mg/1oralPd Rx Pharmaceuticals, Inc.2010-12-13Not applicableUs
Prochlorperazine Maleatetablet, film coated5 mg/1oralA S Medication Solutions Llc1996-11-18Not applicableUs
Prochlorperazine Maleatetablet, film coated10 mg/1oralPhysicians Total Care, Inc.2000-01-07Not applicableUs
Prochlorperazine Maleatetablet5 mg/1oralProficient Rx LP1998-03-01Not applicableUs
Prochlorperazine Maleatetablet, film coated10 mg/1oralMylan Pharmaceuticals Inc.1996-11-18Not applicableUs
Prochlorperazine Maleatetablet, film coated10 mg/1oralMylan Institutional Inc.1997-04-15Not applicableUs
Prochlorperazine Maleatetablet, film coated10 mg/1oralCardinal Health2011-01-28Not applicableUs
Prochlorperazine Maleatetablet10 mg/1oralDispensing Solutions, Inc.1998-03-01Not applicableUs
Prochlorperazine Maleatetablet, film coated10 mg/1oralLake Erie Medical DBA Quality Care Products LLC2012-11-05Not applicableUs
Prochlorperazine Maleatetablet, film coated5 mg/1oralMylan Pharmaceuticals Inc.1996-11-18Not applicableUs
Prochlorperazine Maleatetablet, film coated5 mg/1oralA S Medication Solutions Llc1996-11-18Not applicableUs
Prochlorperazine Maleatetablet10 mg/1oralProficient Rx LP1998-03-01Not applicableUs
Prochlorperazine Maleatetablet10 mg/1oralRebel Distributors Corp1998-03-01Not applicableUs
Prochlorperazine Maleatetablet, film coated5 mg/1oralMylan Institutional Inc.1997-04-15Not applicableUs
Prochlorperazine Maleatetablet, film coated10 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Prodcuts LLC2011-12-06Not applicableUs
Prochlorperazine Maleatetablet5 mg/1oralBlenheim Pharmacal, Inc.2011-04-01Not applicableUs
Prochlorperazine Maleatetablet5 mg/1oralJUBILANT CADISTA PHARMACEUTICALS, INC.1998-03-01Not applicableUs
Prochlorperazine Maleatetablet, film coated10 mg/1oralPreferred Pharmaceuticals, Inc2012-04-05Not applicableUs
Prochlorperazine Maleatetablet5 mg/1oralREMEDYREPACK INC.2011-06-30Not applicableUs
Prochlorperazine Maleatetablet, film coated10 mg/1oralTeva Pharmaceuticals USA Inc1996-07-25Not applicableUs
Prochlorperazine Maleatetablet, film coated5 mg/1oralA S Medication Solutions Llc1996-07-25Not applicableUs
Prochlorperazine Maleatetablet, film coated10 mg/1oralA S Medication Solutions Llc1996-07-25Not applicableUs
Prochlorperazine Maleatetablet, film coated10 mg/1oralAvera Mc Kennan Hospital2015-05-20Not applicableUs
Prochlorperazine Maleatetablet5 mg/1oralRebel Distributors Corp1998-03-01Not applicableUs
Prochlorperazine Maleatetablet, film coated10 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2010-12-13Not applicableUs
Prochlorperazine Maleatetablet, film coated10 mg/1oralA S Medication Solutions Llc1996-07-19Not applicableUs
Prochlorperazine Maleatetablet, film coated10 mg/1oralCardinal Health1996-07-19Not applicableUs
Prochlorperazine Maleatetablet10 mg/1oralAidarex Pharmaceuticals LLC1998-03-01Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
BuccastemReckitt Benckiser
EmetiralZentiva
StemzineSanofi-Aventis
VoliminChin Teng
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Prochlorperazine dimaleate
ThumbNot applicableDBSALT001627
Prochlorperazine edisylate
ThumbNot applicableDBSALT000999
Prochlorperazine maleate
ThumbNot applicableDBSALT000998
Categories
UNIIYHP6YLT61T
CAS number58-38-8
WeightAverage: 373.943
Monoisotopic: 373.13794618
Chemical FormulaC20H24ClN3S
InChI KeyInChIKey=WIKYUJGCLQQFNW-UHFFFAOYSA-N
InChI
InChI=1S/C20H24ClN3S/c1-22-11-13-23(14-12-22)9-4-10-24-17-5-2-3-6-19(17)25-20-8-7-16(21)15-18(20)24/h2-3,5-8,15H,4,9-14H2,1H3
IUPAC Name
2-chloro-10-[3-(4-methylpiperazin-1-yl)propyl]-10H-phenothiazine
SMILES
CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(Cl)C=C3)CC1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenothiazines. These are polycyclic aromatic compounds containing a phenothiazine moiety, which is a linear tricyclic system that consists of a two benzene rings joined by a para-thiazine ring.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzothiazines
Sub ClassPhenothiazines
Direct ParentPhenothiazines
Alternative Parents
Substituents
  • Phenothiazine
  • Alkyldiarylamine
  • Diarylthioether
  • N-alkylpiperazine
  • N-methylpiperazine
  • Piperazine
  • 1,4-diazinane
  • Aryl halide
  • Aryl chloride
  • Para-thiazine
  • Tertiary aliphatic amine
  • Tertiary amine
  • Azacycle
  • Thioether
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the symptomatic management of psychotic disorders, short term management of nonpsychotic anxiety in patients with generalized anxiety disorder, and for the control of severe nausea and vomiting of various causes.
PharmacodynamicsProchlorperazine is a piperazine phenothiazine related to high-potency neuroleptics such as perphenazine. It shares many of the actions and adverse effects of the antipsychotics.
Mechanism of actionThe mechanism of action of prochlorperazine has not been fully determined, but may be primarily related to its antidopaminergic effects. Prochlorperazine blocks the D2 somatodendritic autoreceptor, resulting in the blockade of postsynaptic dopamine receptors in the mesolimbic system and an increased dopamine turnover. Prochlorperazine also has anti-emetic effects, which can be attributed to dopamine blockade in the chemoreceptor trigger zone. Prochlorperazine also blocks anticholinergic and alpha-adrenergic receptors, the blockade of alpha(1)-adrenergic receptors resulting in sedation, muscle relaxation, and hypotension.
Related Articles
AbsorptionRapidly absorbed following oral administration
Volume of distributionNot Available
Protein binding91-99%
Metabolism

Hepatic. Undergoes metabolism in the gastric mucosa and on first pass through the liver, CYP2D6 and/or CYP3A4.

Route of eliminationNot Available
Half life6 to 8 hours
ClearanceNot Available
ToxicitySymptoms of central nervous system depression to the point of somnolence or coma. Agitation and restlessness may also occur. Other possible manifestations include convulsions, EKG changes and cardiac arrhythmias, fever and autonomic reactions such as hypotension, dry mouth and ileus; LD50=400mg/kg (orally in mice)
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9821
Blood Brain Barrier+0.9781
Caco-2 permeable+0.7729
P-glycoprotein substrateSubstrate0.8537
P-glycoprotein inhibitor IInhibitor0.817
P-glycoprotein inhibitor IIInhibitor0.8577
Renal organic cation transporterInhibitor0.7615
CYP450 2C9 substrateNon-substrate0.7702
CYP450 2D6 substrateNon-substrate0.5179
CYP450 3A4 substrateNon-substrate0.5346
CYP450 1A2 substrateInhibitor0.9376
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorInhibitor0.9723
CYP450 2C19 inhibitorInhibitor0.8994
CYP450 3A4 inhibitorNon-inhibitor0.7676
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8557
Ames testNon AMES toxic0.8999
CarcinogenicityNon-carcinogens0.9456
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.3496 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8165
hERG inhibition (predictor II)Inhibitor0.786
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Glaxosmithkline
  • Paddock laboratories inc
  • Able laboratories inc
  • G and w laboratories inc
  • Alpharma us pharmaceuticals division
  • Morton grove pharmaceuticals inc
  • Baxter healthcare corp anesthesia and critical care
  • Bedford laboratories div ben venue laboratories inc
  • Hospira inc
  • Marsam pharmaceuticals llc
  • Smith and nephew solopak div smith and nephew
  • Teva parenteral medicines inc
  • Watson laboratories inc
  • Wyeth ayerst laboratories
  • Duramed pharmaceuticals inc sub barr laboratories inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Mylan pharmaceuticals inc
  • Sandoz inc
  • Teva pharmaceuticals usa
  • Cadista pharmaceuticals inc
Packagers
Dosage forms
FormRouteStrength
Suppositoryrectal25 mg/1
Solutionintramuscular; intravenous5 mg
Suppositoryrectal10 mg
Tabletoral10 mg
Tabletoral5 mg
Injectionintramuscular5 mg/mL
Injectionintramuscular; intravenous10 mg/2mL
Injectionintramuscular; intravenous5 mg/mL
Tabletoral10 mg/1
Tabletoral5 mg/61
Tabletoral5 mg/1
Tablet, film coatedoral10 mg/1
Tablet, film coatedoral5 mg/1
Liquidintramuscular; intravenous5 mg
Syruporal5 mg
Prices
Unit descriptionCostUnit
Prochlorperazine mal powder4.77USD g
Compazine 25 mg suppository4.25USD suppository
Prochlorperazine 25 mg suppository3.13USD suppository
Compro 25 mg suppository3.05USD suppository
Compazine 5 mg tablet1.82USD tablet
Compazine 10 mg tablet1.8USD tablet
Prochlorperazine 5 mg/ml vial1.22USD ml
Prochlorperazine 5 mg/ml0.91USD ml
Prochlorperazine Maleate 10 mg tablet0.88USD tablet
Sandoz Prochlorperazine 10 mg Suppository0.87USD suppository
Prochlorperazine 10 mg tablet0.85USD tablet
Prochlorperazine Maleate 5 mg tablet0.59USD tablet
Prochlorperazine 5 mg tablet0.57USD tablet
Apo-Prochlorazine 10 mg Tablet0.21USD tablet
Apo-Prochlorazine 5 mg Tablet0.17USD tablet
Novamine 15% iv solution0.09USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point228 °CPhysProp
water solubility15 mg/L (at 24 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP4.88HANSCH,C ET AL. (1995)
logS-4.4ADME Research, USCD
pKa8.1SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.011 mg/mLALOGPS
logP4.67ALOGPS
logP4.38ChemAxon
logS-4.5ALOGPS
pKa (Strongest Basic)8.39ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area9.72 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity109.81 m3·mol-1ChemAxon
Polarizability41.77 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (10.4 KB)
Spectra
Spectrum TypeDescriptionSplash Key
MSMass Spectrum (Electron Ionization)splash10-022c-9752000000-533ac31876b44d82f2aaView in MoNA
References
Synthesis Reference

DrugSyn.org

US2902484
General ReferencesNot Available
External Links
ATC CodesN05AB04
AHFS Codes
  • 28:16.08.24
  • 56:22.08
PDB EntriesNot Available
FDA labelDownload (617 KB)
MSDSDownload (73.7 KB)
Interactions
Drug Interactions
Drug
AclidiniumAclidinium may increase the anticholinergic activities of Prochlorperazine.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Prochlorperazine.
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
AmisulprideThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Prochlorperazine.
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Prochlorperazine.
AmphetamineProchlorperazine may decrease the stimulatory activities of Amphetamine.
AzelastineProchlorperazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Prochlorperazine.
BenzphetamineProchlorperazine may decrease the stimulatory activities of Benzphetamine.
Botulinum Toxin Type AProchlorperazine may increase the anticholinergic activities of Botulinum Toxin Type A.
Botulinum Toxin Type BProchlorperazine may increase the anticholinergic activities of Botulinum Toxin Type B.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Prochlorperazine.
BromocriptineThe therapeutic efficacy of Prochlorperazine can be decreased when used in combination with Bromocriptine.
BuprenorphineProchlorperazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Prochlorperazine.
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Prochlorperazine.
Calcium carbonateCalcium carbonate can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
CathinoneProchlorperazine may decrease the stimulatory activities of Cathinone.
Cimetropium BromideProchlorperazine may increase the anticholinergic activities of Cimetropium Bromide.
CitalopramThe risk or severity of adverse effects can be increased when Citalopram is combined with Prochlorperazine.
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Prochlorperazine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Prochlorperazine.
DeferoxamineThe risk or severity of adverse effects can be increased when Deferoxamine is combined with Prochlorperazine.
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Prochlorperazine.
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Prochlorperazine.
DextroamphetamineProchlorperazine may decrease the stimulatory activities of Dextroamphetamine.
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Prochlorperazine.
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Prochlorperazine.
DofetilideThe serum concentration of Dofetilide can be increased when it is combined with Prochlorperazine.
DonepezilDonepezil may increase the central neurotoxic activities of Prochlorperazine.
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Prochlorperazine.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Prochlorperazine.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Prochlorperazine.
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Prochlorperazine.
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Prochlorperazine.
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Prochlorperazine.
EluxadolineProchlorperazine may increase the activities of Eluxadoline.
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Prochlorperazine.
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Prochlorperazine.
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Prochlorperazine.
EscitalopramThe risk or severity of adverse effects can be increased when Escitalopram is combined with Prochlorperazine.
EthanolProchlorperazine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Prochlorperazine.
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Prochlorperazine.
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Prochlorperazine.
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Prochlorperazine.
GalantamineGalantamine may increase the central neurotoxic activities of Prochlorperazine.
Glucagon recombinantThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Glucagon recombinant.
HydrocodoneProchlorperazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Prochlorperazine.
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Prochlorperazine.
Ipratropium bromideIpratropium bromide may increase the anticholinergic activities of Prochlorperazine.
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Prochlorperazine.
ItoprideThe therapeutic efficacy of Itopride can be decreased when used in combination with Prochlorperazine.
LevomilnacipranThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Prochlorperazine.
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Prochlorperazine.
LisdexamfetamineProchlorperazine may decrease the stimulatory activities of Lisdexamfetamine.
LithiumLithium may increase the neurotoxic activities of Prochlorperazine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Prochlorperazine.
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Prochlorperazine.
Magnesium oxideMagnesium oxide can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Prochlorperazine.
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Prochlorperazine.
MequitazineProchlorperazine may increase the arrhythmogenic activities of Mequitazine.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Prochlorperazine.
MethamphetamineProchlorperazine may decrease the stimulatory activities of Methamphetamine.
MethotrimeprazineProchlorperazine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
MethylphenidateThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Methylphenidate.
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Prochlorperazine.
MetyrosineProchlorperazine may increase the sedative activities of Metyrosine.
MianserinMianserin may increase the anticholinergic activities of Prochlorperazine.
MilnacipranThe risk or severity of adverse effects can be increased when Milnacipran is combined with Prochlorperazine.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Prochlorperazine.
MirabegronThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Mirabegron.
MirtazapineProchlorperazine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Prochlorperazine.
MorphineProchlorperazine may increase the hypotensive activities of Morphine.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Prochlorperazine.
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Prochlorperazine.
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Prochlorperazine.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Prochlorperazine.
OrphenadrineProchlorperazine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
ParaldehydeProchlorperazine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParoxetineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Paroxetine.
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Prochlorperazine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Prochlorperazine.
PhendimetrazineProchlorperazine may decrease the stimulatory activities of Phendimetrazine.
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Prochlorperazine.
PhentermineProchlorperazine may decrease the stimulatory activities of Phentermine.
PorfimerProchlorperazine may increase the photosensitizing activities of Porfimer.
Potassium ChlorideProchlorperazine may increase the ulcerogenic activities of Potassium Chloride.
PramlintidePramlintide may increase the anticholinergic activities of Prochlorperazine.
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Prochlorperazine.
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Prochlorperazine.
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Prochlorperazine.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Prochlorperazine.
PyrimethamineThe serum concentration of Prochlorperazine can be increased when it is combined with Pyrimethamine.
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Prochlorperazine.
RamosetronProchlorperazine may increase the activities of Ramosetron.
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Prochlorperazine.
RivastigmineRivastigmine may increase the central neurotoxic activities of Prochlorperazine.
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Prochlorperazine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Prochlorperazine.
SecretinThe therapeutic efficacy of Secretin can be decreased when used in combination with Prochlorperazine.
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Prochlorperazine.
SertralineThe risk or severity of adverse effects can be increased when Sertraline is combined with Prochlorperazine.
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Prochlorperazine.
SulpirideThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Sulpiride.
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Prochlorperazine.
SuvorexantProchlorperazine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
TacrineThe therapeutic efficacy of Prochlorperazine can be decreased when used in combination with Tacrine.
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Prochlorperazine.
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Prochlorperazine.
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Prochlorperazine.
ThalidomideProchlorperazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThiopentalThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Thiopental.
TiotropiumProchlorperazine may increase the anticholinergic activities of Tiotropium.
TopiramateThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Topiramate.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Prochlorperazine.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Prochlorperazine.
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Prochlorperazine.
TrichlormethiazideThe serum concentration of Trichlormethiazide can be increased when it is combined with Prochlorperazine.
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Prochlorperazine.
UmeclidiniumUmeclidinium may increase the anticholinergic activities of Prochlorperazine.
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Prochlorperazine.
VerteporfinProchlorperazine may increase the photosensitizing activities of Verteporfin.
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Prochlorperazine.
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Prochlorperazine.
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Prochlorperazine.
ZolpidemProchlorperazine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Food Interactions
  • Avoid alcohol.
  • Take with a full glass of water Avoid excessive quantities of coffee or tea (Caffeine).
  • Take with food.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Potassium channel regulator activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
DRD2
Uniprot ID:
P14416
Molecular Weight:
50618.91 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Roberge RJ: Antiemetic-related dystonic reaction unmasked by removal of a scopolamine transdermal patch. J Emerg Med. 2006 Apr;30(3):299-302. [PubMed:16677982 ]
  3. Hamik A, Peroutka SJ: Differential interactions of traditional and novel antiemetics with dopamine D2 and 5-hydroxytryptamine3 receptors. Cancer Chemother Pharmacol. 1989;24(5):307-10. [PubMed:2527092 ]
  4. Vinson DR: Development of a simplified instrument for the diagnosis and grading of akathisia in a cohort of patients receiving prochlorperazine. J Emerg Med. 2006 Aug;31(2):139-45. [PubMed:17044574 ]
  5. Callan JE, Kostic MA, Bachrach EA, Rieg TS: Prochlorperazine vs. promethazine for headache treatment in the emergency department: a randomized controlled trial. J Emerg Med. 2008 Oct;35(3):247-53. doi: 10.1016/j.jemermed.2007.09.047. Epub 2008 Jun 5. [PubMed:18534808 ]
  6. Narita M, Takei D, Shiokawa M, Tsurukawa Y, Matsushima Y, Nakamura A, Takagi S, Asato M, Ikegami D, Narita M, Amano T, Niikura K, Hashimoto K, Kuzumaki N, Suzuki T: Suppression of dopamine-related side effects of morphine by aripiprazole, a dopamine system stabilizer. Eur J Pharmacol. 2008 Dec 14;600(1-3):105-9. doi: 10.1016/j.ejphar.2008.10.030. Epub 2008 Oct 21. [PubMed:18955042 ]
  7. Golembiewski J, Tokumaru S: Pharmacological prophylaxis and management of adult postoperative/postdischarge nausea and vomiting. J Perianesth Nurs. 2006 Dec;21(6):385-97. [PubMed:17169748 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on February 04, 2016 11:51